23 Feb Avectas
Michael Maguire, Ph.D., CEO
Oct. 7 | 9:15am | FLW Ballroom F
Kildare, Ireland
(Private)
Avectas is an enabling technology company advancing the scalable, cost-effective manufacturing of gene-modified cell therapies, including CAR-T therapy. The company has developed Solupore®: a closed, automated, integrated, GMP-ready manufacturing platform that enables the efficient production of cell therapies such as CAR-T for immuno-oncology and autoimmune disease, from development to commercial scale. In the past 12 months, Solupore has progressed significantly beyond its core non-viral transfection capability to incorporate multiple manufacturing steps including activation, transduction, transfection, proliferation, and harvest into a single-use consumable system. Standard manufacturing workflows typically rely on multiple devices and reagents, limiting scalability. Solupore addresses these constraints by integrating key processes and enabling safe parallel processing of closed consumables on a single controller device, increasing both equipment and suite throughput while maintaining viability, potency, and functionality of engineered cells. Avectas has filed Device and Drug Master Files (DMFs) to support regulatory adoption of the Solupore platform.
